The prevalence of obesity and related metabolic disorders increases rapidly in western societies. A proper choice of foods may now prevent or delay many of the health consequences related to these disorders. In this respect, replacing dietary saturated fatty acids (SFAs) by cis-monounsaturated fatty acids (cis-MUFAs) has beneficial effects. In addition to diet-derived cis-MUFAs, the human body can also generate cis-MUFAsfrom SFAs through the action of stearoyl-CoA desaturases (SCDs). SCDs may play an adverse role in obesity and obesity-related insulin resistance. Here, we review the current knowledge on the molecular aspects and the role of SCD1 in obesity and the metabolic syndrome (MS). In mice, many studies have suggested a negative role for SCD1 in the development of obesity and insulin resistance. In humans, however, evidence is less convincing. If anything, increased, rather than decreased, levels of SCD1 mRNA levels are negatively associated with MS-related diseases such as insulin resistance. However, an unequivocal conclusion is currently not possible as the number of human studies is limited. Therefore, more human studies are needed at the molecular as well as at the physiological level to understand the true role of SCD1 during the development of obesity and the MS.
Introduction
Obesity is a major risk factor for chronic diseases such as the metabolic syndrome (MS), diabetes mellitus type 2, hypertension and cardiovascular diseases. Currently, obesity has reached epidemic proportions and is globally recognized as a growing medical problem. 1 Over one billion adults are overweighed and at least 300 million adults are obese. Moreover, these numbers are increasing rapidly, not only in adults but also in children. 2, 3 There is no common denominator to explain these increasing numbers, though it is has been observed that obesity is significantly associated with an increased consumption of energy-dense food, together with a reduced level of physical activity. [4] [5] [6] [7] Dietary fat is an important macronutrient in the diet. It is a source of energy and it plays a pivotal role in many cellular processes. Moreover, dietary fatty acids are able to affect gene expression, leading to pronounced changes in metabolism, cell differentiation and growth. 8 Replacing, for example, cis-monounsaturated fatty acids (cis-MUFAs) with saturated fatty acids (SFAs) in the diet may impair insulin sensitivity, one of the characteristics of the MS, and may increase the risk to develop type 2 diabetes. 9, 10 In addition, the proportions of the SFA palmitic acid (C16:0) and stearic acid (18:0) of plasma phospholipids correlated positively with the development of type 2 diabetes. 11 Further, the SFA palmitic acid (C16:0) and stearic acid (18:0) significantly downregulated levels of peroxisome proliferator-activated receptor gamma coactivator-1a (PGC-1a) and peroxisome proliferator-activated receptor gamma coactivator-1b (PGC-1b) mRNA, whereas the cis-MUFA, palmitoleic acid (C16:1) and oleic acid (C18:1), did not change mRNA expression of PGC1a and PGC-1b. 12 Changes in the regulation of PGC-1a and PGC-1b in mice and human are associated with obesity and the MS, but their precise roles are not fully understood and may be tissue specific. [12] [13] [14] As desaturase enzymes modulate the fatty acid composition of cellular lipids, they can also indirectly influence gene transcription, fat storage and insulin sensitivity. The human desaturases comprises d5, d6 and d9 desaturases. Stearoyl-CoA desaturases (SCDs; EC 1.14.19.1) belongs to the group of enzymes that introduce a cis double bond between carbon atoms C9 and C10 of the fatty acid chain, counted from the carbon atom of the carboxyl end. Therefore, SCD is also called d9 desaturase. The mammalian SCDs are located in the membrane of the endoplasmatic reticulum. On the basis of the topology of mouse SCD1, it is thought that the N-terminus of the enzyme is in contact with the cytoplasm, spans the endoplasmatic reticulum and also makes contact with the endoplasmatic reticulum lumen. 15 SCD works together with NADH-cytochrome b5 reductase and cytochrome b5 to desaturate fatty acids. 16, 17 The availability of SCD protein is rate limiting in the conversion of SFAs to MUFAs. 18 SCDs are widely found in various species such as human, mice, rats, hamsters, sheep, fish, plants, fungi and nematodes. [19] [20] [21] [22] [23] [24] [25] [26] [27] In humans, SCD1 is a key enzyme in the biosynthesis of the cis-MUFA, palmitoleic acid (C16:1) and oleic acid (C18:1) from its preferred SFA substrates palmitic acid (C16:0) and stearic acid (C18:0), respectively 28 ( Figure 1 ). However, considering that rat SCD can act on chain lengths from C12:0 up to C19:0, other fatty acids may also serve as substrate. 28 In mice, four SCD isoforms have been identified. 25, [29] [30] [31] Mouse SCD1, SCD2 and SCD4 desaturate both stearic acid (C18:0) and palmitic acid (C16:0), but mouse SCD3 utilizes only palmitic acid (C16:0). 32 Mouse SCD1 is mainly expressed in white adipose tissue, liver, lung, and skin, whereas SCD2 is constitutively expressed in brain, at much lower levels in adipose tissue, lung, skin and liver. 30, 33 SCD3 is expressed exclusively in skin 31 and SCD4 predominately in heart. 29 There are two SCD enzymes of human origin; SCD1 and SCD2 (or SCD5). 22, [34] [35] [36] The human SCD1
and SCD2 have similar desaturase activities toward 14 C-labeled stearic acid (C18:0) and palmitic acid (C16:0) (35, 36) . The human SCD1 mRNA is predominately expressed in adipose tissue and liver and to a lesser extent in lung, brain and the pancreas. 35 SCD2 mRNA is mainly expressed in brain, pancreas, kidneys and lungs. When compared to these tissues, low expression levels of SCD1 and SCD2 mRNA are detectable in human muscle and heart tissue. 35 This observation suggests that skeletal muscle and heart muscle tissue depend for their necessary MUFAs and PUFAs (polyunsaturated fatty acids) on the uptake of these fatty acids from the environment. Another possibility is that there might be a third or even fourth human SCD isoform. However, as far as known, there are no studies that clearly demonstrate desaturase activity in human muscle. In one study, however, increased SCD1 mRNA levels were observed in skeletal muscle tissue of morbid obese human when compared to lean subjects, but it cannot be excluded that this SCD1 mRNA originated from inter muscular fat cells. 37 The role, function and regulation of SCD have been studied in different processes. There are indications that SCD plays an important role in membrane fluidity. In addition, SCD expression may be changed during the development of cancer. 22, 38 Interestingly, SCD1 mRNA and protein upregulation correlates with neural regeneration in rat. 39 Also, in human SCD1 and especially SCD2 mRNA is highly upregulated human fetal brain, suggesting a role for SCD in human brain development. 35 This is supported by data derived from the nematode Caenorhabditis elegans. In this nematode, the SCDs (fat-5, 6 and 7) are essential for MUFA and PUFA production. Knockdown of the SCDs in this worm results in growth retardation and shorter life span. 19 Furthermore, research of the past decade in mice suggests an important function of SCD in obesity, obesity-related insulin resistance and diabetes mellitus type 2.
In this review, the regulation of SCD is first described, followed by a discussion on the effects of SCD on membrane fluidity and cancer development. Finally, an overview of the role of SCD1 in relation to the MS and obesity is given.
Regulation of SCD
The human SCD family is composed of two genes, SCD1 and SCD2. SCD1 is located on chromosome 10 34 at 10q24.31 and SCD2 on chromosome 4 at 4q21.22. 36 Human SCD genes are highly related to the SCD genes from other species and all share three highly conserved histidine motives. 40, 41 These histidine motives are thought to bind an iron atom and are essential for the enzymatic activity. 40 The consensus
is obtained using the ClustalW sequence alignment program from the software package of Vector NTI Suite 10 (Invitrogen Corporation, Carlsbad, USA) on all SCD from the EC 1.14.19.1 group (Figure 2 ). With this consensus sequence, it might be possible to discover new SCD isoforms of human origin and of other species. Humans have two SCD1 genes, of which one is a pseudo gene. The putative mRNA transcript that could arise from this pseudo gene has two premature in-frame stop codons. The pseudo gene has no introns and is located on chromosome 17 at 17p11.2, whereas the functional SCD1 gene is located on chromosome 10. 34 In contrast to the mRNA of the SCD1 gene, the pseudogene mRNA could not be detected in the brain and liver. 34 Therefore, the SCD1 pseudogene is considered to be transcriptional inactive or to produce an Peroxisome proliferator-activated receptors (PPARs) are another group of transcription factors involved in lipid and glucose metabolism. Activation of PPARs reduces the risk to develop atherosclerosis and has positive effects on the lipid profile and insulin sensitivity. Importantly, the human promoter of SCD1 45 contains also other binding sites such as the binding site for the PPARs, which is similar to the PPAR binding site in the mice SCD1 promotor. 47 So far, the postulated link between human SCD1 and its regulation via the PPARs needs to be established. Considering that PPARs are tightly linked to lipid and carbohydrate metabolism, it is plausible that these transcription factors are also able to regulate SCD. This is supported by the finding that PPAR agonists are able to increase the SCD1 mRNA levels in humans, mouse and rats. [47] [48] [49] However, mouse SCD2 seems to be regulated independent of PPARs. 47 To modulate SCD expression and thereby its protein level using diet or drugs, it is crucial to understand the regulation of the synthesis and the activity of the SCD protein. The SCD enzymes seem to be tightly regulated at both the transcriptional and protein level. SCD have a high turnover of approximately 3-4 h. 50, 51 In rat, the N-terminus of SCD1
contains a sequence motive of 33-66 residues that triggers SCD1 for rapid degradation. 52, 53 More specifically, three lysyl residues (positions 33, 35 and 36) may be essential for the initiation of SCD degradation, whereas substitution of these lysyl residues with alanyl residues resulted in stabilization of the SCD protein without affecting its enzymatic activity. 54 As these amino acids are highly conserved in rat and humans, it is likely that also the human SCD have a similar fast turnover. SCD1 degradation, which is likely to occur on the cytoplasmic site of the endoplasmatic reticulum, is independent of the lysosome or proteosome as its degradation could not be blocked by lysosomal or proteosome inhibitors. 52, 55 Therefore, it was suggested that degradation of SCD1 was partially performed by a lysosome and proteosome independent serine or thiol protease, such as the plasminogen (PGL)-like protein. 56, 57 However, both overexpression and downregulation of PGL showed no changes in SCD1 degradation. 53 Later studies from Kato et al., 53 however, clearly indicated that the degradation of SCD1 is dependent on ubiquitinization and is mediated via the proteosome. In these later studies, SCD1 protein degradation was studied using cells instead of microsomal fractions. [55] [56] [57] Considering that these later studies used a more physiologically relevant approach, these findings support the notion that SCD1 is most likely subjected to ubiquitinization-mediated degradation rather than degradation by serine or thiol proteases.
Role of SCD1 in membrane fluidity
For a normal cellular function, it is necessary to maintain proper cell membrane fluidity. By increasing the proportion of unsaturated fatty acids, membranes become more fluid thereby countering the increased membrane stiffness during cold. In this way, the membrane fluidity can be maintained under various temperatures. As recently reviewed by Aguilar and De Mendoza, 43 SCD together with other desaturases such as d5 and d6 are thought to be involved in maintaining Stearoyl-CoA desaturases and the metabolic syndrome HE Popeijus et al cell membrane fluidity. This view is supported by the observation that SCD1 regulates membrane fluidity in Simian vacuolating virus 40 (SV40) transformed human lung fibroblasts. 58 Additional evidence is derived from bacteria, fungi, fish, and plants in which a decrease in temperature induces the rapid transcriptional upregulation of the SCD. 20, [59] [60] [61] [62] [63] Other interesting findings are derived from experiments with carp, a fish with two known SCD genes, SCD1 and SCD2, respectively. In these fish, there is a difference in upregulation of the SCD isoforms. Carp SCD1 is upregulated by a SFA-enriched diet, whereas Carp SCD2 is upregulated by lowering the temperature of the water. 44, 61 However, it remains to be elucidated whether this role of SCD is important in humans as well.
Role of SCD1 in the link between obesity and cancer
Data from prospective epidemiological studies showed that obesity was associated with an increased risk to develop various from of cancers. 64, 65 Another study found that obesity was positively associated with death due to prostate cancer metastases. 66 Hursting et al. 67 2007 now suggested that the observed increase in obesity associated cancers is the result of chronic inflammation that follows obesity. Also SCDs may play a role in cancer development. 22 SV40
transformation leads to oncogenic transformation of primary fibroblasts. It has now been observed that SCD1 is strongly upregulated in SV40-transformed fibroblasts. 58 Therefore, SCD1 has been linked to increased neoplastic cell transformation and to a process that protects the neoplastic cell against apoptosis. 58 In contrast, strongly downregulated or even diminished SCD1 expression is often seen in human prostate carcinoma. 68 Interestingly, fatty acid synthase is highly upregulated in both SV40 transformed fibroblast and prostate carcinoma, as well as in many other tumor types. 22, 58, 69 Inhibition of fatty acid synthase is linked to induced cell death, [70] [71] [72] whereas overexpression predicts prostate cancer progression. 73 Furthermore, recent data indicated downregulation of SCD1 protein in some tumor cell lines. 38 SCD1 knockdown resulted in 40% cell survival in the human non-small cell lung carcinoma cell line (H1299), 75% survival in human colon cancer cells, whereas human breast carcinoma cell line MDA-MB-468 seemed unaffected. 38 The decrease in cell survival through apoptosis was thought to be mediated via upregulation of Caspase 3.
38
Thus, it remains currently unclear whether SCD plays a key role in tumor genesis.
The role of SCD in the metabolic syndrome and obesity
Overweighed and obese subjects are at increased risk to develop the MS. SCD1 is now thought to serve as a potential molecular target to prevent or treat this highly prevalent disease. SCD1 is thought to stimulate fat storage in adipose tissue. Therefore, it has been postulated that inhibition of the SCD1 activity could attenuate obesity through redistribution of fat toward utilization and blockage of fat storage. Evidence for this hypothesis is mostly derived from mice. The SCD1-null mice (abJ/abJ, SCD1 À/À) are protected from development of insulin resistance even after overfeeding conditions. [74] [75] [76] These mice are insulin sensitive probably as a consequence of their inability to become obese. In contrast, their littermates, that did have a functional SCD1, became obese and insulin insensitive. [74] [75] [76] In addition to SCD1-null mice, normal mice treated with antisense oligos to specifically downregulate SCD1 mRNA were also leaner, more insulin sensitive and became resistant to diet-induced obesity. 77 The littermates of the SCD1-null mice and normal mice that were treated with scrambled (nonsense) antisense oligos became obese and insulin resistant following overfeeding. [75] [76] [77] Moreover, hepatic SCD1 mRNA levels were elevated in insulin-resistant obese (ob/ob) mice and in obesity prone mice. 78, 79 Furthermore, when mice were fed a high-fat diet to induce insulin resistance, SCD1 mRNA levels increased. These data have led to the hypothesis that SCD genes are potential candidates to target with drugs or diet to treat obesity and insulin resistance. However, contradictory evidence has been published. High fat-feeding in rats resulted in SCD1 mRNA levels less than 20% of normal SCD1 mRNA levels. 80 Furthermore, one study showed that overexpression of SCD1 protein in rat muscle cells, protected them against fatty acid-induced insulin resistance. 81 In addition, in rats made diabetic with streptozotocin, SCD1 mRNA levels were significantly decreased. 82 Furthermore, in obese and insulin resistant aP2-nSREBP-1c mice, SCD1 mRNA levels and activity in liver are strongly upregulated. 79 In these mice, leptin is able to completely reduce SCD1 mRNA levels and activity, comparable to wild-type levels. As a result, these animals become insulin sensitive. 79 Crossing aP2-nSREBP-1c mice with SCD1-null (abJ/abJ, SCD1À/À) mice reduced their liver steatosis and diminished their white adipose tissue. 79 Interestingly, these mice were still diabetic and had high plasma glucose levels, even higher than aP2-nSREBP-1c mice, which was probably due to b-cell failure. 79 Similar results were observed, when leptin null (ob/ob) mice were crossed with SCD1-null (SCD1À/À) mice. Their offspring had reduced body weight and increased insulin resistance. 76 These data suggest that the positive effects of leptin are uncoupled from SCD1 mRNA levels and activity, and that the loss of SCD1 in these double knockout mice enhance insulin resistance. In humans, data concerning SCDs in relation to the MS is scarce. As SCD genes are probably negatively related to obesity, one could assume that genetic variation in these genes would make one more or less susceptible to the development of obesity. However, single nucleotide polymorphism analysis of the human SCD1 gene revealed no association with BMI, waist-to-hip ratio and chromosome Stearoyl-CoA desaturases and the metabolic syndrome HE Popeijus et al 10-linked type 2 diabetes. 83 However, recently eight single nucleotide polymorphisms of the human SCD1 gene were reported to be associated with obesity and obesity-related insulin resistance. 84 Other contradictory evidence emerged from a study with obese diabetic patients treated with rosiglitazone to counter their insulin resistance. In these patients, SCD1 mRNA levels were elevated instead of downregulated. 48 Obese and insulin-resistant patients treated with rosiglitazone gain some weight as a consequence of the treatment. 85 However, their insulin resistance decreases probably due to a lowering of circulating free fatty acid levels. The latter may be related to increased SCD1 mRNA levels and subsequent enhanced fat storage. Thus, these data may indicate that SCD1 protects rather than induces obesity and insulin resistance. The contradictory evidence that increased SCD1 mRNA is protective might be explained by differences in fat metabolism in mice compared to humans and rats. In SCD1 knockout mice, fat oxidation is increased probably via uncoupling proteins present in the brown adipose tissue. Similarly, when diet-induced obese and insulin-resistant mice were treated with a PPARg antagonist, uncoupling protein-2 levels and fat utilization increased, whereas SCD1 mRNA levels decreased in skeletal muscle and white adipose tissue. In fact, these mice also lost weight and became less insulin resistant. 86 Therefore, despite similarities in genes, mice handle fat metabolism by different mechanisms than humans. All together, these findings indicate that decreasing SCD1 expression in mice may protect against obesity and can attenuate insulin resistance. In man, however, evidence is less convincing. If anything, increased, rather than decreased, levels of SCD1 mRNA levels are negatively associated with MS-related diseases such as insulin resistance. Thus, for humans, an unequivocal conclusion is currently not possible as the number of studies is too limited. Therefore, more data from human studies are needed before SCDs can be considered as a promising target to counter obesity and the MS.
